Catalio Capital Management LP Invests $35.51 Million in Gilead Sciences, Inc. $GILD

Catalio Capital Management LP purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, HoldingsChannel reports. The fund purchased 289,312 shares of the biopharmaceutical company’s stock, valued at approximately $35,510,000. Gilead Sciences makes up approximately 6.6% of Catalio Capital Management LP’s investment portfolio, making the stock its largest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new position in Gilead Sciences during the fourth quarter worth about $2,617,152,000. Boston Partners purchased a new position in Gilead Sciences during the fourth quarter worth about $517,808,000. Massachusetts Financial Services Co. MA raised its stake in Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares during the period. Bank of America Corp DE raised its stake in Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Vanguard Group Inc. raised its stake in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 1.4%

Shares of GILD stock opened at $125.45 on Thursday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a market capitalization of $155.75 billion, a P/E ratio of 17.09 and a beta of 0.31. The company has a 50 day moving average price of $132.31 and a 200 day moving average price of $134.30. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is 44.69%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 68,000 shares of company stock worth $8,930,150. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on GILD shares. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Argus lifted their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Truist Financial reaffirmed a “buy” rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Leerink Partners reduced their target price on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Finally, Citigroup lifted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $158.41.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA accepted Gilead’s filing for once-weekly oral Yeztugo for HIV prevention, a key step that could expand the company’s long-acting PrEP franchise and create a new growth opportunity if approved. FDA Accepts Gilead’s Filing for Weekly Oral Yeztugo for HIV Prevention
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $155 price target, indicating analyst confidence in upside from current levels. Benzinga report on Cantor Fitzgerald rating
• Positive Sentiment: Gilead donated more than 2,000 vials of remdesivir to Uganda to support Ebola response efforts, which may help reinforce the company’s public-health profile, though the direct financial impact appears limited. Gilead Sciences Donates Remdesivir to Uganda
• Neutral Sentiment: Two senior insiders, including CFO Andrew D. Dickinson and executive Johanna Mercier, sold shares under pre-arranged 10b5-1 plans. These sales are routine and not necessarily a bearish signal, but they can still pressure sentiment. SEC filing for Andrew D. Dickinson sale SEC filing for Johanna Mercier sale
• Neutral Sentiment: The stock had recently been under mild pressure and is still trading below key moving averages, so the latest move looks more like a reaction to the mixed news flow than a change in fundamentals. Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.